Search

Search Constraints

You searched for: Author/Creator Wu, Zhouliang

Search Results

5. MP59-19 UPDATE OF TRUCE-02: AN OPEN LABEL, SINGLE-ARM, PHASE 2 STUDY OF TILELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR HIGH-RISK NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (HR-NMIBC) WHICH IS NOT COMPLETELY RESECTABLE. (May 2022)

6. Nanoparticle-based combination of LMWH and doxorubicin for the efficient treatment of hepatocellular carcinoma with portal vein tumor thrombus. (April 2023)

7. PD10-07 UPDATE OF TRUCE-01: NEOADJUVANT TISLELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA. (May 2022)

8. Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug. Issue 20 (7th May 2022)

9. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study. Issue 5 (February 2016)

10. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study. Issue 5 (February 2016)